Literature DB >> 24817556

A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.

Chunyan Cai1, Suyu Liu, Ying Yuan.   

Abstract

Interim monitoring is routinely conducted in phase II clinical trials to terminate the trial early if the experimental treatment is futile. Interim monitoring requires that patients' responses be ascertained shortly after the initiation of treatment so that the outcomes are known by the time the interim decision must be made. However, in some cases, response outcomes require a long time to be assessed, which causes difficulties for interim monitoring. To address this issue, we propose a Bayesian trial design to allow for continuously monitoring phase II clinical trials in the presence of delayed responses. We treat the delayed responses as missing data and handle them using a multiple imputation approach. Extensive simulations show that the proposed design yields desirable operating characteristics under various settings and dramatically reduces the trial duration.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  continuous monitoring; delayed responses; multiple imputation

Mesh:

Year:  2014        PMID: 24817556      PMCID: PMC4435968          DOI: 10.1002/sim.6200

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  23 in total

1.  A modification of Simon's optimal design for phase II trials when the criterion is median sample size.

Authors:  J J Hanfelt; R S Slack; E A Gehan
Journal:  Control Clin Trials       Date:  1999-12

2.  Bayesian two-stage designs for phase II clinical trials.

Authors:  Say-Beng Tan; David Machin
Journal:  Stat Med       Date:  2002-07-30       Impact factor: 2.373

3.  Optimal two-stage designs for single arm phase II cancer trials.

Authors:  Jonathan Shuster
Journal:  J Biopharm Stat       Date:  2002-02       Impact factor: 1.051

4.  Planned versus attained design in phase II clinical trials.

Authors:  S J Green; S Dahlberg
Journal:  Stat Med       Date:  1992-05       Impact factor: 2.373

5.  A Bayesian predictive two-stage design for phase II clinical trials.

Authors:  Valeria Sambucini
Journal:  Stat Med       Date:  2008-04-15       Impact factor: 2.373

6.  Bayesian design of single-arm phase II clinical trials with continuous monitoring.

Authors:  Valen E Johnson; John D Cook
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

7.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

8.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.

Authors:  P F Thall; R M Simon; E H Estey
Journal:  Stat Med       Date:  1995-02-28       Impact factor: 2.373

9.  An optimal three-stage design for phase II clinical trials.

Authors:  L G Ensign; E A Gehan; D S Kamen; P F Thall
Journal:  Stat Med       Date:  1994-09-15       Impact factor: 2.373

10.  One-sample multiple testing procedure for phase II clinical trials.

Authors:  T R Fleming
Journal:  Biometrics       Date:  1982-03       Impact factor: 2.571

View more
  7 in total

Review 1.  Future prospects of therapeutic clinical trials in acute myeloid leukemia.

Authors:  Maliha Khan; Armaghan-E-Rehman Mansoor; Tapan M Kadia
Journal:  Future Oncol       Date:  2016-10-24       Impact factor: 3.404

2.  Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.

Authors:  Rebecca S Slack Tidwell; S Andrew Peng; Minxing Chen; Diane D Liu; Ying Yuan; J Jack Lee
Journal:  Clin Trials       Date:  2019-08-26       Impact factor: 2.486

3.  A novel evaluation of optimality for randomized controlled trials.

Authors:  Jo Wick; Scott M Berry; Hung-Wen Yeh; Won Choi; Christina M Pacheco; Christine Daley; Byron J Gajewski
Journal:  J Biopharm Stat       Date:  2016-06-13       Impact factor: 1.051

4.  A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.

Authors:  Jian Wang; Junsheng Ma; Chunyan Cai; Naval Daver; Jing Ning
Journal:  Stat Med       Date:  2021-06-07       Impact factor: 2.497

5.  Comparing Bayesian early stopping boundaries for phase II clinical trials.

Authors:  Liyun Jiang; Fangrong Yan; Peter F Thall; Xuelin Huang
Journal:  Pharm Stat       Date:  2020-07-27       Impact factor: 1.234

6.  A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research.

Authors:  Chunyan Cai; Mohammad H Rahbar; Md Monir Hossain; Ying Yuan; Nicole R Gonzales
Journal:  Contemp Clin Trials Commun       Date:  2017-05-06

7.  Applied Bayesian Approaches for Research in Motor Neuron Disease.

Authors:  Anna G M Temp; Marcel Naumann; Andreas Hermann; Hannes Glaß
Journal:  Front Neurol       Date:  2022-03-24       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.